Abstract:DNA methylation is a fundamental modification characterized by the addition of a methyl group to the cytosine bases of DNA and plays an important role in regulating gene expression, maintaining genome stability, and influencing cellular differentiation. Since the identification of abnormal DNA methylation in primary human tumors, comprehensive research has been conducted and strongly demonstrates that distorted DNA methylation patterns in cancer can lead to the silencing of inhibitory genes and the activation of oncogenes, thereby promoting tumorigenesis, progression, and resistance to treatment. These alterations in the methylation landscape present both challenges and opportunities for cancer treatment: it cannot only serve as hallmark features of cancer for early detection and monitoring treatment response, but also offer unique insights into potential therapeutic targets and new treatment strategies. The exploration of the molecular mechanisms underlying the changes in DNA methylation levels highlights the intricate relationship between DNA methylation, gene regulation, and cancer pathophysiology, allowing researchers to identify potential therapeutic targets that can effectively and safely inhibit the growth of cancer cells. This research topic aims to explore the complexity of DNA methylation in cancer therapy, highlighting its significance as a biomarker for diagnosis and prognosis, as well as a promising avenue for innovative treatment strategies.Zhang et al., attempted to develop a prognostic model for hepatocellular carcinoma (HCC) based on the expression of DNA methylation-related genes to identify potential therapeutic targets and predict overall survival. The researchers analyzed the transcriptomic, clinical, and DNA methylation data from The Cancer Genome Atlas Liver Hepatocellular Carcinoma database and the GSE54236 liver cancer dataset. They identified three methylation-related differential genes-GLS, MEX3B, and GNA14and established a risk score model to predict patient prognosis. The model was validated using an independent dataset, and its accuracy was further confirmed through qRT-PCR and immunohistochemistry. The study concluded that the gene signature could provide reliable predictions for clinical applications and enhance the understanding of the mechanisms behind the occurrence and progression of HCC.Liu et al., investigated the correlation between TERT promoter methylation and its expression levels in papillary thyroid cancer (PTC). By analyzing 571 PTC samples from The Cancer Genome Atlas (TCGA), the researchers found that patients with TERT hypermethylation had significantly higher expression level and poorer clinical outcomes compared to those with TERT hypomethylation. Additionally, the study demonstrated that treatment with the demethylating agent decitabine reduced TERT expression and cell viability in PTC cell lines. The findings suggest that TERT promoter methylation can serve as a prognostic marker for PTC risk stratification. The research enhances our understanding of the epigenetic mechanisms underlying the progression of PTC and provides a potential target for therapeutic intervention.Peng et al., explored the role of DNA methylation in hepatocellular carcinoma (HCC), focusing on how methylation modifications influence the tumor microenvironment (TME) and the efficacy of immunotherapy. Through a comprehensive analysis of DNA methylation regulators and TME profiles in HCC, the researchers identified three distinct methylation patterns, each with unique TME characteristics. They developed a DNA methylation score (DMscore) to evaluate individual methylation levels, which could predict patient subtype, TME infiltration, and prognosis. A low DMscore, indicative of an inflamed TME with high tumor mutation burden (TMB) and viral infection, was associated with poor survival outcomes. This study suggests that the DMscore can serve as a valuable biomarker for survival and immunotherapy response in HCC patients, potentially aiding in the optimization of immunotherapy approaches.Li et al., investigates the association between MGMT promoter methylation, CD47, and TIGIT expression levels and their impact on patient prognosis in adult diffuse gliomas (ADG). This study reclassified ADG into astrocytoma, oligodendroglioma, and glioblastoma (GBM) based on the 2021 WHO classification system. The findings revealed that higher CD47 and TIGIT expression levels in tumor tissues are associated with poorer overall survival rates. Notably, MGMT unmethylation is linked to a poor prognosis in astrocytoma patients. The study suggests that patients with elevated CD47 and TIGIT expression may benefit from anti-CD47 and TIGIT immunotherapy, highlighting the potential of these markers for therapeutic intervention in ADG. However, due to the unbalanced sample size of ADG subtypes and the lack of treated patients, this study acknowledges limitations which p -Abstract Truncated-

Characterizing the mutational burden, DNA methylation landscape, and proteome of germ cell tumor-related somatic-type malignancies to identify the tissue-of-origin, mechanisms of therapy resistance, and druggable targets

Differential methylation EPIC analysis discloses cisplatin-resistance related hypermethylation and tumor-specific heterogeneity within matched primary and metastatic testicular germ cell tumor patient tissue samples

Genome Wide DNA Methylation Profiles Provide Clues to the Origin and Pathogenesis of Germ Cell Tumors

Integrated Molecular Characterization of Testicular Germ Cell Tumors.

Molecular and epigenetic ex vivo profiling of testis cancer-associated fibroblasts and their interaction with germ cell tumor cells and macrophages

Molecular analysis of primary testicular germ cell tumor and matched metastatic teratomas.

Analysis of the genomic landscape of yolk sac tumors reveals mechanisms of evolution and chemoresistance

Recent Advancements in Research on DNA Methylation and Testicular Germ Cell Tumors: Unveiling the Intricate Relationship

Morphological spectrum and molecular features of somatic malignant transformation in germ cell tumours

Abstract 2856: Multi-omics approaches for biomarker discovery and target therapy in pediatric germ cell tumors

Evolution of Testicular Germ Cell Tumors in the Molecular Era With Histogenetic Implications

Novel molecular aberrations involved in testicular germ cell tumor (TGCT) development and cisplatin resistance.

Comprehensive Genomic Profiling Alters Clinical Diagnoses in a Significant Fraction of Tumors Suspicious of Sarcoma

Integrated genomic analysis reveals aberrations in WNT signaling in germ cell tumors of childhood and adolescence

Multi-omic and functional analysis for classification and treatment of sarcomas with FUS-TFCP2 or EWSR1-TFCP2 fusions

Integrative multi-omic cancer profiling reveals DNA methylation patterns associated with therapeutic vulnerability and cell-of-origin

Comprehensive genetic analysis of pediatric germ cell tumors identifies potential drug targets

Editorial: DNA methylation in cancer therapy: therapeutic targets and molecular mechanism

Origin of Subsequent Malignant Neoplasms in Patients with History of Testicular Germ Cell Tumor

Abstract 7014: Integrative DNA methylation cancer profiling reveals patterns associated with tumor progression and treatment response

Germline determinants of the prostate tumor genome